Life sciences partner Katherine Wang (Shanghai) was named to the China Business Law Journal’s “A-List” of top 100 private practice lawyers for the China market.
The A-List, which recognizes the best legal partners to handle significant transactions and matters in China-related businesses, is based on surveys of thousands of in-house counsel in China and around the world, as well as partners at Chinese and international law firms.
Ms. Wang is a leading regulatory attorney in China’s life sciences community. She assists hospitals, pharmaceutical, biotechnology and medical device companies with a wide range of commercial and regulatory matters, including early stage discovery, product registration, pricing, reimbursement, clinical studies, promotional practices and product safety matters. She represents life sciences companies in response to various inquiries from agencies including the China Food and Drug Administration and the State Administration for Industry and Commerce. She also assists institutional investors and corporate clients in structuring transactions and conducting regulatory due diligence, including good manufacturing practice and pharmacovigilance, on investment targets and prospective business partners in China.
Ms. Wang is highly recognized in Asia, particularly in the life sciences industry. She has been ranked in Chambers Asia (2011-2016) and Chambers Global (2015-2016), Asian Legal Business’ Client Choice Top 20 Lawyers in China (2014 and 2016) and many other premier publications and directories.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.